Consolidation Radiotherapy after Carboplatin-Based Chemotherapy in Radically Operated Advanced Ovarian Cancer

Pickel, H.; Lahousen, M.; Petru, Edgar; Stettner, Haro; Hackl, A.; Kapp, Karin S.; Winter, Raimund

doi:10.1006/gyno.1998.5184

Cited by 71 publications

(38 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Whole abdominal radiotherapy as a consolidation concept after surgery and chemotherapy has been evaluated in several small and nonrandomized studies with contradictory results (12)(13)(14)(15)(16)(17). The recent randomized trial of Sorbe (18) indicated that WAR may have a place in the treatment of advanced ovarian carcinoma in patients with complete pathologic remission after adjuvant chemotherapy.…”

Section: Introductionmentioning

confidence: 97%

Intensity-Modulated Whole Abdominal Radiotherapy After Surgery and Carboplatin/Taxane Chemotherapy for Advanced Ovarian Cancer: Phase I Study

Rochet

Sterzing

Jensen

et al. 2010

International Journal of Radiation Oncology*Biology*Physics

View full text Add to dashboard Cite

Section: Introductionmentioning

confidence: 97%

Intensity-Modulated Whole Abdominal Radiotherapy After Surgery and Carboplatin/Taxane Chemotherapy for Advanced Ovarian Cancer: Phase I Study

Rochet

Sterzing

Jensen

et al. 2010

International Journal of Radiation Oncology*Biology*Physics

View full text Add to dashboard Cite

“…Since the fields are usually very large (40 cm × 30 cm or larger), most patients experience severe side effects, especially myelosuppression. Many of the randomized trials comparing WAI and chemotherapy failed to show a statistically significant difference in overall survival, mainly because of disruption of radiation treatment due to hematologic toxicity [7,20,21].…”

Section: Introductionmentioning

confidence: 99%

Helical Tomotherapy as a New Treatment Technique for Whole Abdominal Irradiation

et al. 2008

View full text Add to dashboard Cite

show abstract

“…Hence, it is usually identified in late stages with poor prognosis. Chemotherapy and radiotherapy are currently in use in patients with ovarian cancer (Pickel et al, 1999). However, these are associated with resistance or damage to normal cells.…”

mentioning

confidence: 99%

Activation of Checkpoint Kinase 2 by 3,3′-Diindolylmethane Is Required for Causing G₂/M Cell Cycle Arrest in Human Ovarian Cancer Cells

Kandala¹,

Srivastava

2010

Mol Pharmacol

View full text Add to dashboard Cite

We evaluated the effect of 3,3Ј-diindolylmethane (DIM) in ovarian cancer cells. DIM treatment inhibited the growth of SKOV-3, TOV-21G, and OVCAR-3 ovarian cancer cells in both a doseand time-dependent manner with effective concentrations ranging from 40 to 100 M. Growth-inhibitory effects of DIM were mediated by cell cycle arrest in G 2 /M phase in all the three cell lines. G 2 /M arrest was associated with DNA damage as indicated by phosphorylation of H 2 A.X at Ser139 and activation of checkpoint kinase 2 (Chk2) in all the three cell lines. Other G 2 /M regulatory molecules such as Cdc25C, Cdk1, cyclin B1 were down-regulated by DIM. Cycloheximide or Chk2 inhibitor pretreatment abrogated not only activation of Chk2 but also G 2 /M arrest and apoptosis mediated by DIM. To further establish the involvement of Chk2 in DIM-mediated G 2 /M arrest, cells were transfected with dominant-negative Chk2 (DN-Chk2). Blocking Chk2 activation by DN-Chk2 completely protected cells from DIM-mediated G 2 /M arrest. These results were further confirmed in Chk2 knockout DT40 lymphoma cells, in which DIM failed to cause cell cycle arrest. These results clearly indicate the requirement of Chk2 activation to cause G 2 /M arrest by DIM in ovarian cancer cells. Moreover, blocking Chk2 activation also abrogates the apoptosis-inducing effects of DIM. Furthermore, our results show that DIM treatment cause ROS generation. Blocking ROS generation by N-acetyl cysteine protects the cells from DIM-mediated G 2 /M arrest and apoptosis. Our results establish Chk2 as a potent molecular target of DIM in ovarian cancer cells and provide the rationale for further clinical investigation of DIM.

show abstract

Consolidation Radiotherapy after Carboplatin-Based Chemotherapy in Radically Operated Advanced Ovarian Cancer

Cited by 71 publications

References 12 publications

Intensity-Modulated Whole Abdominal Radiotherapy After Surgery and Carboplatin/Taxane Chemotherapy for Advanced Ovarian Cancer: Phase I Study

Intensity-Modulated Whole Abdominal Radiotherapy After Surgery and Carboplatin/Taxane Chemotherapy for Advanced Ovarian Cancer: Phase I Study

Helical Tomotherapy as a New Treatment Technique for Whole Abdominal Irradiation

Activation of Checkpoint Kinase 2 by 3,3′-Diindolylmethane Is Required for Causing G₂/M Cell Cycle Arrest in Human Ovarian Cancer Cells

Contact Info

Product

Resources

About

Consolidation Radiotherapy after Carboplatin-Based Chemotherapy in Radically Operated Advanced Ovarian Cancer

Cited by 71 publications

References 12 publications

Intensity-Modulated Whole Abdominal Radiotherapy After Surgery and Carboplatin/Taxane Chemotherapy for Advanced Ovarian Cancer: Phase I Study

Intensity-Modulated Whole Abdominal Radiotherapy After Surgery and Carboplatin/Taxane Chemotherapy for Advanced Ovarian Cancer: Phase I Study

Helical Tomotherapy as a New Treatment Technique for Whole Abdominal Irradiation

Activation of Checkpoint Kinase 2 by 3,3′-Diindolylmethane Is Required for Causing G2/M Cell Cycle Arrest in Human Ovarian Cancer Cells

Contact Info

Product

Resources

About

Activation of Checkpoint Kinase 2 by 3,3′-Diindolylmethane Is Required for Causing G₂/M Cell Cycle Arrest in Human Ovarian Cancer Cells